Lead-212 conjugated NNV-003 (Nordic Nanovector/Orano Med)

N/A

Report date: 2025/11/10 17:58:29

Base Information

Drug NameLead-212 conjugated NNV-003 (Nordic Nanovector/Orano Med)
Drug Alias NameNNV-013212Pb-NNV-003
ClassificationBiologics > Protein drugs > Immunoglobulin > AntibodyRadiation-emitting products > Nuclides > Lead > 212PbRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionIonising radiation emittersLeukocyte antigen CD37 antagonists
TargetsLeukocyte antigen CD37
Therapy Area/IndicationsLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOrano Med LlcNordic Nanovector
China Registration ClassN/A

Develop Information

Active CompaniesOrano Med LlcNordic Nanovector
Inactive CompaniesN/A
Active IndicationsLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A